Eli Lilly投资4.5B美元给Lilly药品铸造厂,用于药物开发和制造。 Eli Lilly invests $4.5B in Lilly Medicine Foundry for drug development and manufacturing.

Eli Lilly & Co公司正在Lilly Medical Foundry投资45亿美元,这是一家侧重于提高药物开发和制造效率的新设施。 Eli Lilly & Co is investing $4.5 billion in the Lilly Medicine Foundry, a new facility focused on enhancing drug development and manufacturing efficiency. 这一举措是在GLP-1肥胖症治疗方案(Mounjaro和Zepbound)取得成功之后采取的,预计到2024年将产生近190亿美元。 This initiative follows the success of its GLP-1 obesity treatments, Mounjaro and Zepbound, projected to generate nearly $19 billion by 2024. 该设施还将支持研究阿尔茨海默氏症和ALS等病症。 The facility will also support research for conditions like Alzheimer's and ALS. 尽管短期股票市场面临挑战,但公司的长期前景仍然乐观。 Despite short-term stock market challenges, the company’s long-term outlook remains positive.